Glomerular Hyperfiltration and Hypertrophy: an Evaluation of Maximum Values in Pathological Indicators to Discriminate "diseased" from "normal"

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Jul 31

PMID 37521339

Authors

Hiroshi Kataoka

Kosaku Nitta

Junichi Hoshino

Affiliations

Soon will be listed here.

Abstract

The success of sodium-glucose cotransporter 2 inhibitors and bariatric surgery in patients with chronic kidney disease has highlighted the importance of glomerular hyperfiltration and hypertrophy in the progression of kidney disease. Sustained glomerular hyperfiltration and hypertrophy can lead to glomerular injury and progressive kidney damage. This article explores the relationship between obesity and chronic kidney disease, focusing on the roles of glomerular hyperfiltration and hypertrophy as hallmarks of obesity-related kidney disease. The pathological mechanisms underlying this association include adipose tissue inflammation, dyslipidemia, insulin resistance, chronic systemic inflammation, oxidative stress, and overactivation of the sympathetic nervous system, as well as the renin-angiotensin aldosterone system. This article explains how glomerular hyperfiltration results from increased renal blood flow and intraglomerular hypertension, inducing mechanical stress on the filtration barrier and post-filtration structures. Injured glomeruli increase in size before sclerosing and collapsing. Therefore, using extreme values, such as the maximal glomerular diameter, could improve the understanding of the data distribution and allow for better kidney failure predictions. This review provides important insights into the mechanisms underlying glomerular hyperfiltration and hypertrophy and highlights the need for further research using glomerular size, including maximum glomerular profile, calculated using needle biopsy specimens.

References

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D . Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24):2295-2306. DOI: 10.1056/NEJMoa1811744. View

da Silva A, do Carmo J, Li X, Wang Z, Mouton A, Hall J . Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Can J Cardiol. 2020; 36(5):671-682. PMC: 7219403. DOI: 10.1016/j.cjca.2020.02.066. View

Thomas M, Lemaitre M, Wilson M, Viboud C, Yordanov Y, Wackernagel H . Applications of Extreme Value Theory in Public Health. PLoS One. 2016; 11(7):e0159312. PMC: 4946775. DOI: 10.1371/journal.pone.0159312. View

Spoto B, Pisano A, Zoccali C . Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016; 311(6):F1087-F1108. DOI: 10.1152/ajprenal.00340.2016. View

Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K . Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56(4):901-11. DOI: 10.2337/db06-0911. View

Berthoux F, Mariat C, Maillard N . Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. 2013; 28 Suppl 4:iv160-6. DOI: 10.1093/ndt/gft286. View

Chen Y, Dabbas W, Gangemi A, Benedetti E, Lash J, Finn P . Obesity Management and Chronic Kidney Disease. Semin Nephrol. 2021; 41(4):392-402. DOI: 10.1016/j.semnephrol.2021.06.010. View

Cahill M, RYAN G, Bertram J . Biphasic glomerular hypertrophy in rats administered puromycin aminonucleoside. Kidney Int. 1996; 50(3):768-75. DOI: 10.1038/ki.1996.375. View

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

10.

Hall J, do Carmo J, da Silva A, Wang Z, Hall M . Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15(6):367-385. PMC: 7278043. DOI: 10.1038/s41581-019-0145-4. View

11.

Wang M, Wang Z, Chen Y, Dong Y . Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs. Int J Mol Sci. 2022; 23(2). PMC: 8775419. DOI: 10.3390/ijms23020747. View

12.

Feinstein A . X and iprP: an improved summary for scientific communication. J Chronic Dis. 1987; 40(4):283-8. DOI: 10.1016/0021-9681(87)90043-9. View

13.

Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U . Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000; 278(5):F817-22. DOI: 10.1152/ajprenal.2000.278.5.F817. View

14.

Kataoka H, Ono K, Mochizuki T, Hanafusa N, Imai E, Hishida A . A Body Mass Index-Based Cross-Classification Approach for the Assessment of Prognostic Factors in Chronic Kidney Disease Progression. Kidney Blood Press Res. 2019; 44(3):362-383. DOI: 10.1159/000501021. View

15.

Denic A, Mathew J, Lerman L, Lieske J, Larson J, Alexander M . Single-Nephron Glomerular Filtration Rate in Healthy Adults. N Engl J Med. 2017; 376(24):2349-2357. PMC: 5664219. DOI: 10.1056/NEJMoa1614329. View

16.

Lane P, Steffes M, MAUER S . Estimation of glomerular volume: a comparison of four methods. Kidney Int. 1992; 41(4):1085-9. DOI: 10.1038/ki.1992.165. View

17.

Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T . Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2006; 71(2):159-66. DOI: 10.1038/sj.ki.5002017. View

18.

Tobar A, Ori Y, Benchetrit S, Milo G, Herman-Edelstein M, Zingerman B . Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PLoS One. 2013; 8(9):e75547. PMC: 3783420. DOI: 10.1371/journal.pone.0075547. View

19.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

20.

DAgati V . Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol. 2003; 23(2):117-34. DOI: 10.1053/snep.2003.50012. View